Drug repositioning and repurposing for Alzheimer disease

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

Dementia prevention, intervention, and care

Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072 · see citing works

The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease

Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257 · see citing works

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396 · see citing works

α-Synuclein Locus Triplication Causes Parkinson's Disease

Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383 · see citing works

A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles

Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515 · see citing works

Cholinesterase inhibitors for Alzheimer's disease

Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906 · see citing works

β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression

Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518 · see citing works

Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis

Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin, L. J., & Kuncl, R. W. (1995) · Annals of Neurology · doi:10.1002/ana.410380114 · Cited by 1,471 · see citing works

The Study on Cognition and Prognosis in the Elderly (SCOPE)

Lithell, H., Hansson, L., Skoog, I. G., Elmfeldt, D., Albert Hofman, D., Olofsson, B., Trenkwalder, P., & Zanchetti, A. (2003) · Journal of Hypertension · doi:10.1097/00004872-200305000-00011 · Cited by 1,413 · see citing works

Untitled work

Williamson (2019) · doi:10.1001/jama.2018.21442 · Cited by 1,246 · see citing works

Donepezil for dementia due to Alzheimer’s disease.

Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200 · see citing works

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · see citing works

Mild Cognitive Impairment

Petersen, R. C. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000313 · Cited by 925 · see citing works

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698 · see citing works

Herpes simplex virus type 1 in brain and risk of Alzheimer's disease

Itzhaki, R. F., Lin, W., Shang, D., Wilcock, G. K., Faragher, B. E., & Jamieson, G. A. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10149-5 · Cited by 671 · see citing works

Randomized trial of verubecestat for prodromal Alzheimer's disease

Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545 · see citing works

Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease

Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522 · see citing works

Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier

Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480 · see citing works

Indexed Pain Journals

(U.S.), N. L. O. M. (2008) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360280801989377 · Cited by 474 · see citing works

Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques

Wozniak, M., Mee, A., & Itzhaki, R. (2009) · The Journal of Pathology · doi:10.1002/path.2449 · Cited by 464 · see citing works

β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease

Mittal, S., Bjørnevik, K., Im, D. S., Flierl, A., Dong, X., Locascio, J. J., Abo, K. M., Long, E., Jin, M., Xu, B. Y., et al. (2017) · Science · doi:10.1126/science.aaf3934 · Cited by 417 · see citing works

Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections—a Nationwide, Population-Based Cohort Study in Taiwan

Tzeng, N.-S., Chung, C.-H., Lin, F.-H., Chiang, C.-P., Yeh, C.-B., Huang, S.-Y., Lu, R.-B., Chang, H.-A., Kao, Y.-C., Yeh, H.-W., et al. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0611-x · Cited by 356 · see citing works

Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron

Perry, T., Lahiri, D. K., Sambamurti, K., Chen, D., Mattson, M. P., Egan, J. M., & Greig, N. H. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10611 · Cited by 347 · see citing works

Herpes simplex virus infection causes cellular β-amyloid accumulation and secretase upregulation

Wozniak, M. A., Itzhaki, R. F., Shipley, S. J., & Dobson, C. B. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.09.077 · Cited by 339 · see citing works

Latent herpes simplex virus type 1 in normal and Alzheimer's disease brains

Jamieson, G. A., Maitland, N. J., Wilcock, G. K., Craske, J., & Itzhaki, R. F. (1991) · Journal of Medical Virology · doi:10.1002/jmv.1890330403 · Cited by 333 · see citing works

Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease

Wang, J., Ho, L., Chen, L., Zhao, Z., Zhao, W., Qian, X., Humala, N., Seror, I., Bartholomew, S. R., Rosendorff, C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31547 · Cited by 331 · see citing works

Insulin metabolism and the risk of Alzheimer disease: The Rotterdam Study

Schrijvers, E. M. C., Witteman, J. C. M., Sijbrands, E. J. G., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ffe4f6 · Cited by 328 · see citing works

Drug repositioning and repurposing: terminology and definitions in literature

Langedijk, J., Mantel-Teeuwisse, A. K., Slijkerman, D. S., & Schutjens, M.-H. D. B. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.001 · Cited by 327 · see citing works

Glutamate Transporters in Neurologic Disease

Maragakis, N. J., & Rothstein, J. D. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.365 · Cited by 324 · see citing works

A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.

Perry, T., Lahiri, D., Chen, D., Zhou, J., Shaw, K., Egan, J., & Greig, N. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.958 · Cited by 306 · see citing works

Drug repositioning for Alzheimer's disease

Corbett, A., Pickett, J., Burns, A. S., Corcoran, J. P. T., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 302 · see citing works

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial

Cukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez, L.-E., Lakshmanan, M., Bethel, A., Xavier, D., Probstfield, J., Riddle, M. C., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30173-3 · Cited by 300 · see citing works

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial

Cudkowicz, M., Titus, S., Kearney, M., Yu, H., Sherman, A., Schoenfeld, D., Hayden, D., Shui, A. M., Brooks, B. R., CONWIT, R. A., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70222-4 · Cited by 243 · see citing works

Brain renin-angiotensin—A new look at an old system

Wright, J. W., & Harding, J. W. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.07.001 · Cited by 233 · see citing works

Amantadine

Hubsher, G., Haider, M., & Okun, M. S. (2012) · Neurology · doi:10.1212/wnl.0b013e31824e8f0d · Cited by 229 · see citing works

Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt–PCP–JNK pathway

Killick, R., Ribe, E. M., Al-Shawi, R., Malik, B., Hooper, C., Fernandes, C., Dobson, R., Nolan, P. M., Lourdusamy, A., Furney, S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2012.163 · Cited by 222 · see citing works

Alzheimer’s disease-specific tau phosphorylation is induced by herpes simplex virus type 1

Wozniak, M. A., Frost, A. L., & Itzhaki, R. F. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0963 · Cited by 216 · see citing works

Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies

Anderson, C., Teo, K., Gao, P., Arima, H., Dans, A., Unger, T., Commerford, P., Dyal, L., Schumacher, H., Pogue, J., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70250-7 · Cited by 216 · see citing works

Current advances in using neurotrophic factors to treat neurodegenerative disorders

Weissmiller, A. M., & Wu, C. (2012) · Translational Neurodegeneration · doi:10.1186/2047-9158-1-14 · Cited by 211 · see citing works

Novel GLP‐1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

Hamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210 · see citing works

Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study

van Gool, W. A., Weinstein, H. C., Scheltens, P., & Walstra, G. J. M. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05623-9 · Cited by 210 · see citing works

Efficacy and Safety of Fasudil in Patients With Stable Angina

Vicari, R. M., CHAITMAN, B. R., Keefe, D. L., Smith, W. B., Chrysant, S. G., Tonkon, M. J., Bittar, N., Weiss, R., Morales-Ballejo, H., & Thadani, U. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.07.047 · Cited by 199 · see citing works

Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial

Howard, R., Zubko, O., Bradley, R., Harper, E., Pank, L., O’Brien, J., Fox, C., Tabet, N., Livingston, G., Bentham, P., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3762 · Cited by 194 · see citing works

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. W., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002660 · Cited by 193 · see citing works

The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer’s Disease

Hansen, H. H., Fabricius, K., Barkholt, P., Niehoff, M. L., Morley, J. E., Jelsing, J., Pyke, C., Knudsen, L. B., Farr, S. A., & Vrang, N. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143090 · Cited by 189 · see citing works

Angiotensins in Alzheimer's disease - friend or foe?

Kehoe, P., Miners, S., & Love, S. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.07.006 · Cited by 180 · see citing works

Determining the minimum clinically important differences for outcomes in the DOMINO trial

Howard, R., Phillips, P., Johnson, T., O'Brien, J. T., Sheehan, B., Lindesay, J., Bentham, P., Burns, A., Ballard, C., Holmes, C., et al. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2607 · Cited by 179 · see citing works

Antivirals Reduce the Formation of Key Alzheimer's Disease Molecules in Cell Cultures Acutely Infected with Herpes Simplex Virus Type 1

Wozniak, M. A., Frost, A. L., Preston, C. M., & Itzhaki, R. F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025152 · Cited by 173 · see citing works

Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment

Gejl, M., Brock, B., Egefjord, L., Vang, K., Rungby, J., & Gjedde, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-17718-y · Cited by 163 · see citing works

Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice

Gengler, S., McClean, P. L., McCurtin, R. E., Gault, V. A., & Hölscher, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.02.014 · Cited by 160 · see citing works

A Pilot Study of Exenatide Actions in Alzheimer’s Disease

Mullins, R. J., Mustapić, M., Chia, C. W., Carlson, O. D., Gulyani, S., Tran, J., Li, Y., Mattson, M. P., Resnick, S. M., Egan, J. M., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190913155950 · Cited by 160 · see citing works

Protective Effects of Intranasal Losartan in the APP/PS1 Transgenic Mouse Model of Alzheimer Disease

Danielyan, L., Klein, R., Hanson, L. R., Buadze, M., Schwab, M. G., Gleiter, C. H., & Frey, W. H. (2010) · Rejuvenation Research · doi:10.1089/rej.2009.0944 · Cited by 158 · see citing works

Double-Blind, Placebo-Controlled Clinical Trial With a Rho-Kinase Inhibitor in Pulmonary Arterial Hypertension

Fukumoto, Y., Yamada, N., Matsubara, H., Mizoguchi, M., Uchino, K., Yao, A., Kihara, Y., Kawano, M., Watanabe, H., Takeda, Y., et al. (2013) · Circulation Journal · doi:10.1253/circj.cj-13-0443 · Cited by 151 · see citing works

Herpes Zoster and Dementia: A Nationwide Population-Based Cohort Study

Chen, V. C.-H., Wu, S.-I., Huang, K.-Y., Yang, Y.-H., Kuo, T.-Y., Liang, H.-Y., Huang, K.-L., & Gossop, M. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m11312 · Cited by 142 · see citing works

HSV-1 promotes Ca2+-mediated APP phosphorylation and Aβ accumulation in rat cortical neurons

Piacentini, R., Civitelli, L., Ripoli, C., Marcocci, M. E., Chiara, G. D., Garaci, E., Azzena, G. B., Palamara, A. T., & Grassi, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.06.009 · Cited by 141 · see citing works

Current and emerging avenues for Alzheimer's disease drug targets

Loera‐Valencia, R., Cedazo-Mı́nguez, Á., Kenigsberg, P.-A., Page, G., Duarte, A. I., Giusti, P., Zusso, M., Robert, P. H., Frisoni, G. B., Cattaneo, A., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12959 · Cited by 139 · see citing works

FGF-20, a Novel Neurotrophic Factor, Preferentially Expressed in the Substantia Nigra Pars Compacta of Rat Brain

Ohmachi, S., Watanabe, Y., Mikami, T., Kusu, N., Ibi, T., Akaike, A., & Itoh, N. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3675 · Cited by 139 · see citing works

Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer’s disease model

Ongali, B., Nicolakakis, N., Tong, X., Aboulkassim, T., Papadopoulos, P., Rosa‐Neto, P., Lecrux, C., Imboden, H., & Hamel, É. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.04.018 · Cited by 135 · see citing works

Telmisartan prevented cognitive decline partly due to PPAR-γ activation

Mogi, M., Li, J., Tsukuda, K., Iwanami, J., Min, L., Sakata, A., Fujita, T., Iwai, M., & Horiuchi, M. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.08.032 · Cited by 134 · see citing works

The Experimental Alzheimer’s Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-β Peptide Levels in Cell Culture and Mice

Lahiri, D. K., Chen, D., Maloney, B., Holloway, H. W., Yu, Q.-S., Utsuki, T., Giordano, T., Sambamurti, K., & Greig, N. H. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.112102 · Cited by 134 · see citing works

Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease

Kadir, A., Andreasen, N., Almkvist, O., Wall, A. E., Forsberg, A., Engler, H., Hagman, G., Lärksäter, M., Winblad, B. G., Zetterberg, H., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21345 · Cited by 133 · see citing works

Herpes simplex virus type I induces the accumulation of intracellular β-amyloid in autophagic compartments and the inhibition of the non-amyloidogenic pathway in human neuroblastoma cells

Santana, S., Recuero, M., Bullido, M. J., Valdivieso, F., & Aldudo, J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.12.010 · Cited by 131 · see citing works

Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model

Qi, L., Ke, L., Liu, X., Liao, L., Ke, S., Liu, X., Wang, Y., Lin, X., Zhou, Y., Wu, L., et al. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.04.052 · Cited by 128 · see citing works

Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice

McClean, P. L., Jalewa, J., & Hölscher, C. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.024 · Cited by 125 · see citing works

How Thalidomide Works Against Cancer

Stewart, A. K. (2014) · Science · doi:10.1126/science.1249543 · Cited by 125 · see citing works

An Overview of Phenserine Tartrate, A Novel Acetylcholinesterase Inhibitor for the Treatment of Alzheimers Disease

Greig, N. H., Sambamurti, K., Yu, Q.-S., Brossi, A. R., Bruinsma, G., & Lahiri, D. K. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367829 · Cited by 122 · see citing works

Neuronal Cytoskeletal Dynamic Modification and Neurodegeneration Induced by Infection with Herpes Simplex Virus Type 1

Zambrano, Á., Solís, L., Salvadores, N., Cortés, M., Lerchundi, R., & Carola Otth, L. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14301 · Cited by 120 · see citing works

The renin-angiotensin system in the brain: possible therapeutic implications for AT1-receptor blockers

Čulman, J., Blume, A., Gohlke, P., & Unger, T. (2002) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001442 · Cited by 114 · see citing works

H-Series Protein Kinase Inhibitors and Potential Clinical Applications

Ono-Saito, N., Niki, I., & Hidaka, H. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00070-9 · Cited by 108 · see citing works

Central Angiotensin II Stimulation Promotes β Amyloid Production in Sprague Dawley Rats

Zhu, D., Shi, J., Zhang, Y., Wang, B., Liu, W., Chen, Z., & Tong, Q. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016037 · Cited by 107 · see citing works

Peripheral delivery of a ROCK inhibitor improves learning and working memory.

Huentelman, M. J., Stephan, D. A., Talboom, J. S., Corneveaux, J. J., Reiman, D., Gerber, J. D., Barnes, C. A., Alexander, G. E., Reiman, E. M., & Bimonte‐Nelson, H. A. (2009) · Behavioral Neuroscience · doi:10.1037/a0014260 · Cited by 107 · see citing works

β2‐adrenoceptor agonists and antagonists and risk of Parkinson's disease

Gronich, N., Abernethy, D. R., Auriel, E., Lavi, I., Rennert, G., & Saliba, W. (2018) · Movement Disorders · doi:10.1002/mds.108 · Cited by 107 · see citing works

Rho Kinase Inhibitor Fasudil Protects againstβ-Amyloid-Induced Hippocampal Neurodegeneration in Rats

Song, Y., Chen, X., Wang, L., Gao, W. Q., & Zhu, M.-J. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12116 · Cited by 106 · see citing works

A role for APP in Wnt signalling links synapse loss with β-amyloid production

Elliott, C., Rojo, A. I., Ribé, E. M., Broadstock, M., Xia, W., Morin, P., Semënov, M. V., Baillie, G. S., Cuadrado, A., Al‐Shawi, R., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0231-6 · Cited by 106 · see citing works

Amyloid β synaptotoxicity is Wnt‐PCP dependent and blocked by fasudil

Sellers, K. J., Elliott, C., Jackson, J. D., Ghosh, A., Ribé, E. M., Rojo, A. I., Jarosz-Griffiths, H., Watson, I. A., Xia, W., Semënov, M. V., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.09.008 · Cited by 104 · see citing works

ACE Inhibition with Captopril Retards the Development of Signs of Neurodegeneration in an Animal Model of Alzheimer’s Disease

AbdAlla, S., Langer, A., Fu, X., & Quitterer, U. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140816917 · Cited by 100 · see citing works

Val8-glucagon-like peptide-1 protects against Aβ1–40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats

Wang, X. H., Li, L., Hölscher, C., Pan, Y. F., Chen, X. R., & Qi, J. S. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.08.028 · Cited by 99 · see citing works

Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease

Kume, K., Hanyu, H., Sakurai, H., Takada, Y., Onuma, T., & Iwamoto, T. (2011) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2011.00746.x · Cited by 99 · see citing works

Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine

Marutle, A., Ohmitsu, M., Nilbratt, M., Greig, N., Nordberg, A., & Sugaya, K. (2007) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0705346104 · Cited by 99 · see citing works

Central angiotensin II‐induced Alzheimer‐like tau phosphorylation in normal rat brains

Tian, M., Zhu, D., Xie, W., & Shi, J. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.09.004 · Cited by 97 · see citing works

(Val8) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains

Li, L., Zhang, Z., Hölscher, C., Gao, C., Jiang, Y., & Liu, Y. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.11.005 · Cited by 93 · see citing works

The Neuroprotection of Liraglutide on Alzheimer-Like Learning and Memory Impairment by Modulating the Hyperphosphorylation of Tau and Neurofilament Proteins and Insulin Signaling Pathways in Mice

Xiong, H., Chen, Z., Wang, J., Song, J., Zhao, G., Shen, H., & Deng, Y. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130584 · Cited by 90 · see citing works

Transcriptional signatures of brain aging and Alzheimer’s disease: What are our rodent models telling us?

Hargis, K. E., & Blalock, E. M. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.007 · Cited by 90 · see citing works

Economic analysis of opportunities to accelerate Alzheimer's disease research and development

Scott, T. J., O’Connor, A. C., Link, A. N., & Beaulieu, T. J. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12417 · Cited by 87 · see citing works

β2‐adrenoreceptor medications and risk of Parkinson disease

Nielsen, S. S., Gross, A., Camacho‐Soto, A., Willis, A. W., & Racette, B. A. (2018) · Annals of Neurology · doi:10.1002/ana.25341 · Cited by 86 · see citing works

Alzheimer disease risk genes: 29 and counting

Bertram, L., & Tanzi, R. E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0158-4 · Cited by 84 · see citing works

Antiviral therapy: Valacyclovir Treatment of Alzheimer’s Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial

Devanand, D. P., Andrews, H., Kreisl, W. C., Razlighi, Q. R., Gershon, A. A., Stern, Y., Mintz, A., Wısnıewskı, T., Acosta, E. P., Pollina, J., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-032112 · Cited by 83 · see citing works

Angiotensin IV Receptors Mediate the Cognitive and Cerebrovascular Benefits of Losartan in a Mouse Model of Alzheimer's Disease

Royea, J., Zhang, L., Tong, X., & Hamel, É. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.0329-17.2017 · Cited by 77 · see citing works

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients

Judge, A., Garriga, C., Arden, N., Lovestone, S., Prieto‐Alhambra, D., Cooper, C. C., & Edwards, C. J. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.10.002 · Cited by 76 · see citing works

Pharmacological modulation of Alzheimer's β-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions

Haroutunian, V. H., Greig, N. H., Pei, X., Utsuki, T., Gluck, R., Acevedo, L. D., Davis, K. L., & Wallace, W. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(96)00297-5 · Cited by 75 · see citing works

The Role of GLP-1 in Neuronal Activity and Neurodegeneration

Hölscher, C. (2010) · Vitamins & Hormones · doi:10.1016/b978-0-12-381517-0.00013-8 · Cited by 74 · see citing works

The Renin-Angiotensin System and Antihypertensive Drugs in Alzheimer's Disease: Current Standing of the Angiotensin Hypothesis?

Kehoe, P., & Passmore, P. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111376 · Cited by 73 · see citing works

Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review

Yimer, E. M., Hishe, H. Z., & Tuem, K. B. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00236 · Cited by 72 · see citing works

Phenserine Efficacy in Alzheimer's Disease

Winblad, B. G., Giacobini, E., Frölich, L., Friedhoff, L. T., Bruinsma, G., Becker, R. E., & Greig, N. H. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101311 · Cited by 69 · see citing works

Drug repurposing for Alzheimer’s disease based on transcriptional profiling of human iPSC-derived cortical neurons

Williams, G. H., Gatt, A. P., Clarke, E. E., Corcoran, J. P. T., Doherty, P., Chambers, D. J., & Ballard, C. G. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0555-x · Cited by 69 · see citing works

The Effects of Ramipril in Individuals at Risk for Alzheimer’s Disease: Results of a Pilot Clinical Trial

Wharton, W., Stein, J., Korcarz, C., Sachs, J. F., Olson, S. R., Zetterberg, H., Dowling, M., Ye, S.-Y., Gleason, C., Underbakke, G., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120763 · Cited by 68 · see citing works

A searchable cross-platform gene expression database reveals connections between drug treatments and disease

Williams, G. H. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-12 · Cited by 64 · see citing works

Changes in hippocampal synapses and learning-memory abilities in a streptozotocin-treated rat model and intervention by using fasudil hydrochloride

Hou, Y., Zhou, L., Yang, Q. D., Du, X., Li, M., Yuan, M., & Zhou, Z. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.10.030 · Cited by 62 · see citing works

Tempol and perindopril protect against lipopolysaccharide-induced cognition impairment and amyloidogenesis by modulating brain-derived neurotropic factor, neuroinflammation and oxido-nitrosative stress

Ali, M. R. A., Abo‐Youssef, A. M., Messiha, B. A. S., & Khattab, M. M. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1234-6 · Cited by 62 · see citing works

Increased Dendrite Branching in AβPP/PS1 Mice and Elongation of Dendrite Arbors by Fasudil Administration

Couch, B. A., DeMarco, G. J., Gourley, S. L., & Koleske, A. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091114 · Cited by 50 · see citing works

Tau Cleavage at D421 by Caspase-3 is Induced in Neurons and Astrocytes Infected with Herpes Simplex Virus Type 1

Lerchundi, R., Neira, R., Valdivia, S., Vío, K., Concha, M. I., Zambrano, Á., & Carola Otth, L. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101386 · Cited by 50 · see citing works

Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner

Boshoff, E. L., Fletcher, E. J. R., & Duty, S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.04.017 · Cited by 46 · see citing works

(-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice

Lecca, D., Bader, M., Tweedie, D., Hoffman, A. F., Jung, Y. J., Hsueh, S., Hoffer, B. J., Becker, R. E., Pick, C. G., Lupica, C. R., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104528 · Cited by 45 · see citing works

SPIEDw: a searchable platform-independent expression database web tool

Williams, G. H. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-765 · Cited by 44 · see citing works

Multitarget Therapeutic Effect of Fasudil in APP/PS1transgenic Mice

Yu, J., Lǐ, Y., Liu, C., Wang, Q., Gu, Q., Wang, H., Zhang, G., Xiao, B., & Ma, C. (2017) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666160711104719 · Cited by 44 · see citing works

Brain-Penetrating Angiotensin-Converting Enzyme Inhibitors and Cognitive Change in Patients with Dementia due to Alzheimer's Disease

de Oliveira, F. F., Bertolucci, P. H. F., Chen, E., & Smith, M. D. A. C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132189 · Cited by 43 · see citing works

Triflusal

Murdoch, D., & Plosker, G. L. (2006) · Drugs · doi:10.2165/00003495-200666050-00009 · Cited by 43 · see citing works

Efficient treatment of Parkinson’s disease using ultrasonography-guided rhFGF20 proteoliposomes

Niu, J., Xie, J.-J., Guo, K., Zhang, X., Xia, F., Zhao, X., Song, L., Zhuge, D., Li, X., Zhao, Y., et al. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1482972 · Cited by 42 · see citing works

Emerging treatments for Alzheimer’s disease for non-amyloid and non-tau targets

Khan, A., Corbett, A., & Ballard, C. G. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1326818 · Cited by 42 · see citing works

Practical Issues in Stem Cell Therapy for Alzheimers Disease

Sugaya, K., Kwak, Y., Ohmitsu, O., Marutle, A., Greig, N. H., & Choumrina, E. (2007) · Current Alzheimer Research · doi:10.2174/156720507781788936 · Cited by 41 · see citing works

Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms

Tweedie, D., Fukui, K., Li, Y., Yu, Q.-S., Barak, S., Tamargo, I. A., Rubovitch, V., Holloway, H. W., Lehrmann, E., Wood, W. H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156493 · Cited by 40 · see citing works

(−)-Phenserine inhibits neuronal apoptosis following ischemia/reperfusion injury

Chang, C.-F., Lai, J.-H., Wu, J. C.-C., Greig, N. H., Becker, R. E., Luo, Y., Chen, Y., Kang, S.-J., Chiang, Y. H., & Chen, K. (2017) · Brain Research · doi:10.1016/j.brainres.2017.09.015 · Cited by 38 · see citing works

Inhibition of ACE Retards Tau Hyperphosphorylation and Signs of Neuronal Degeneration in Aged Rats Subjected to Chronic Mild Stress

Abdalla, S., Hakim, A. S. E., Abdelbaset, A., el Faramawy, Y., & Quitterer, U. (2015) · BioMed Research International · doi:10.1155/2015/917156 · Cited by 37 · see citing works

The Rationale and Design of the Reducing Pathology in Alzheimer’s Disease through Angiotensin TaRgeting (RADAR) Trial

Kehoe, P. G., Blair, P. S., Howden, B., Thomas, D. L., Malone, I. B., Horwood, J., Clement, C., Selman, L. E., Baber, H., Lane, A., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170101 · Cited by 35 · see citing works

Losartan improves cerebrovascular function in a mouse model of Alzheimer's disease with combined overproduction of amyloid-β and transforming growth factor-β1

Papadopoulos, P., Tong, X., Imboden, H., & Hamel, É. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16658489 · Cited by 35 · see citing works

Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor

Patel, N., Spangler, E. L., Greig, N. H., Yu, Q., Ingram, D. K., & Meyer, R. C. (1998) · Neuroreport · doi:10.1097/00001756-199801050-00035 · Cited by 27 · see citing works

Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats

Fletcher, E. J. R., Jamieson, A. D., Williams, G. H., Doherty, P., & Duty, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-44803-1 · Cited by 26 · see citing works

The Perils of Alzheimers Drug Development

Schneider, L. S. S., & Lahiri, D. K. (2009) · Current Alzheimer Research · doi:10.2174/156720509787313871 · Cited by 22 · see citing works

(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer’s Disease

Becker, R. E., Greig, N. H., Lahiri, D. K., Bledsoe, J. R., Majercik, S. D., Ballard, C. G., Aarsland, D., Schneider, L. S. S., Flanagan, D. R., Govindarajan, R., et al. (2018) · Current Alzheimer Research · doi:10.2174/1567205015666180110120026 · Cited by 19 · see citing works

Identification of Small Molecule Inhibitors of β-Amyloid Cytotoxicity through a Cell-Based High-Throughput Screening Platform

Seyb, K. I., Schuman, E., Ni, J., et al. (2008) · SLAS DISCOVERY · doi:10.1177/1087057108323909 · Cited by 17 · see citing works

Pfizer abandons research into Alzheimer’s and Parkinson’s diseases

Hawkes, N. (2018) · BMJ · doi:10.1136/bmj.k122 · Cited by 15 · see citing works

Evaluation of Fasudil Hydrochloride Treatment for Wandering Symptoms in Cerebrovascular Dementia with 31P-Magnetic Resonance Spectroscopy and Xe-Computed Tomography

Kamei, S., Oishi, M., & Takasu, T. (1996) · Clinical Neuropharmacology · doi:10.1097/00002826-199619050-00006 · Cited by 15 · see citing works

Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in alzheimer disease

Lahiri, D. K., Alley, G. M., Tweedie, D., et al. (2007) · NeuroMolecular Medicine · doi:10.1007/bf02685889 · Cited by 13 · see citing works

Losartan-Induced Hypotension Leads to Tau Hyperphosphorylation and Memory Deficit

Liu, X.-H., Wang, Z.-H., Xia, Y., Yu, G., Zeng, K., Luo, H.-B., Hu, J.-C., Gong, C., Wang, J.-Z., Zhou, X.-W., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131679 · Cited by 11 · see citing works

Alzheimer’s Disease Progression in the 5×FAD Mouse Captured with a Multiplex Gene Expression Array

Gatt, A. P., Whitfield, D., Ballard, C. G., Doherty, P., & Williams, G. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190805 · Cited by 8 · see citing works

Identifying Novel Candidates for Re-Purposing as Potential Therapeutic Agents for Alzheimer’s diseasePreprint

Ballard, C. G., Creese, B., Gatt, A. P., Doherty, P., Francis, P. T., Whitfield, D., Corbett, A., Corcoran, J., Hanger, D. P., Thuret, S., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/622308 · Cited by 7 · see citing works

Neuroprotective effect of triflusal and its main metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid (HTB), in the postischemic brain

Kim, S.-W., Kyu-Jin, C., Park, J., Yoon, S., & Lee, J.-K. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.02.018 · Cited by 6 · see citing works

Curative effect of Fasudil injection combined with Nimodipine on Alzheimer disease of elderly patients

Zhou, G. (2011) · Journal of Clinical Medicine in Practice · Cited by 5 · see citing works

P4‐017: CLINICAL TRIAL PIPELINES FOR ALZHEIMER'S DISEASE POSE CHALLENGES FOR FUTURE EFFECTIVE TREATMENT AND THERAPIES

Ballard, C. G., & Murphy, C. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.06.2419 · Cited by 4 · see citing works

Preface

Litwack, G. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00021-7 · Cited by 3 · see citing works

Untitled work

(2000) · doi:10.1002/1531-8249(200012)48:6

Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases

Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193 · see citing works

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.

Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138 · see citing works

Fe65-engineered neuronal exosomes encapsulating corynoxine-B ameliorate cognition and pathology of Alzheimer’s disease

Iyaswamy, A., Thakur, A., Guan, X.-J., Krishnamoorthi, S., Fung, T. Y., Lu, K., Gaurav, I., Yang, Z., Su, C.-F., Lau, K.-F., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01657-4 · Cited by 134 · see citing works

Enhancing autophagy in Alzheimer's disease through drug repositioning

Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89 · see citing works

Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer’s disease

Cheng, F., Wang, F., Tang, J., Zhou, Y., Fu, Z., Zhang, P., Haines, J. L., Leverenz, J. B., Gan, L., Hu, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101379 · Cited by 63 · see citing works

Berberine Reduces Aβ42 Deposition and Tau Hyperphosphorylation via Ameliorating Endoplasmic Reticulum Stress

Wu, Y., Chen, Q., Wen, B., Wu, N., He, B., & Chen, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.640758 · Cited by 54 · see citing works

Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease

Padhi, D., & Govindaraju, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00335 · Cited by 47 · see citing works

Artificial intelligence for dementia prevention

Newby, D., Orgeta, V., Marshall, C. R., Lourida, I., Albertyn, C. P., Tamburin, S., Raymont, V., Veldsman, M., Koychev, I., Bauermeister, S., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13463 · Cited by 42 · see citing works

Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort

AbuAlrob, M. A., Itbaisha, A., Abujwaid, Y. K., Abulehia, A., Hussein, A., & Mesraoua, B. (2025) · Journal of Alzheimer's Disease Reports · doi:10.1177/25424823251388650 · Cited by 10 · see citing works

CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease

Lu, W., Kawatani, K., Ren, Y., Nambara, T., Jia, L., Jeevaratnam, S., Lee, E., Martinez, P. R., Izhar, T., Wang, N., et al. (2026) · Alzheimer's Research & Therapy · doi:10.1186/s13195-026-01982-0 · Cited by 4 · see citing works

Treatment Repurposing using Literature-related Discovery

Kostoff, R. N. (2019) · Journal of Scientometric Research · doi:10.5530/jscires.8.2.25 · Cited by 4 · see citing works

A data-driven methodology towards evaluating the potential of drug repurposing hypotheses

Santamaría, L. P., Carro, E. U., Uzquiano, M. D., Menasalvas, E., Gallardo, Y. P., & Rodríguez‐González, A. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.003 · Cited by 22 · see citing works

The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions

Polamreddy, P., & Gattu, N. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.022 · Cited by 119 · see citing works

Drug Repurposing and Multi-Target Therapies

Kumar, A. P., Lukman, S., & Nguyen, M. N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.20160-x · Cited by 2 · see citing works

Faculty Opinions recommendation of Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns.

Rastelli, G., & Pinzi, L. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.740542384.793588144